Evidence map›Paper›PMID 26073533›Full record

ArticleJournal of geriatric oncology2015

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.

K Rebecca Fega, Gregory A Abel, Gabriela Motyckova, Alexander E Sherman, Daniel J DeAngelo, David P Steensma, Ilene Galinsky, Martha Wadleigh, Richard M Stone, Jane A Driver

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of geriatric oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04602273 (Treatment of High Risk Myelodysplastic Syndromes), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04602273 unknown statusnot on this mapstarted 2016, after this paper: background citation

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

TypeobservationalSponsorGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasRan2016 to 2021Enrolled150ConditionsMyelodysplastic SyndromesArmsAzacitidine Injection [Vidaza]
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. [Prognostic value of the FS-15 frailty score in patients with myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Article
  3. Article
  4. Peripheral blood CD3British journal of haematology · 2022
    Article
  5. Article
  6. Article
  7. Review
  8. Integrating patient-centered factors in the risk assessment of MDS.Hematology. American Society of Hematology. Education Program · 2019
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

K Rebecca FegaCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, United States.
Gregory A AbelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Gabriela MotyckovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Alexander E ShermanCollege of Medicine, University of Cincinnati, Cincinnati, OH, United States.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
David P SteensmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Ilene GalinskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Martha WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Jane A DriverDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Geriatric Research Education and Clinical Center, VA Boston Medical Center, Boston, MA, United States; Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: jdriver@partners.org.
Harvard University · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USUniversity of Cincinnati Medical Center · USUniversity of Phoenix · US

Funding

Greater Boston Medical Student Training in Aging ResearchT35AG038027 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DRIVER, JANE A, MCLAUGHLIN-GAVIN, CARA · 2010 to 2024
$991k
NIA NIH HHS #1T35AG038027-02 9NIA NIH HHS T35 AG038027
6 · The paper itself

Abstract

objectivesThe International Prognostic Scoring System (IPSS) is commonly used to predict survival and assign treatment for the myelodysplastic syndromes (MDS). We explored whether self-reported and readily available non-hematologic predictors of survival add independent prognostic information to the IPSS. MATERIALS AND

methodsRetrospective cohort study of consecutive MDS patients ≥age 65 who presented to Dana-Farber Cancer Institute between 2006 and 2011 and completed a baseline quality of life questionnaire. Questions corresponding to functional status and symptoms and extracted clinical-pathologic data from medical records. Kaplan-Meier and Cox proportional hazards models were used to estimate survival.

resultsOne hundred fourteen patients consented and were available for analysis. Median age was 73 years, and the majority of patients were White, were male, and had a Charlson comorbidity score of <2. Few patients (24%) had an IPSS score consistent with lower-risk disease and the majority received chemotherapy. In addition to IPSS score and history of prior chemotherapy or radiation, significant univariate predictors of survival included low serum albumin, Charlson score, performance status, ability to take a long walk, and interference of physical symptoms in family life. The multivariate model that best predicted mortality included low serum albumin (HR=2.3; 95% CI: 1.06-5.14), therapy-related MDS (HR=2.1; 95% CI: 1.16-4.24), IPSS score (HR=1.7; 95% CI: 1.14-2.49), and ease taking a long walk (HR=0.44; 95% CI: 0.23-0.90).

conclusionsIn this study of older adults with MDS, we found that low serum albumin and physical function added important prognostic information to the IPSS score. Self-reported physical function was more predictive than physician-assigned performance status.

Indexed as

Surveys and QuestionnairesAgedAged, 80 and overCohort StudiesComorbidityFemaleGeriatric AssessmentHumansMaleMyelodysplastic SyndromesPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSelf ReportSurvival AnalysisElderlyGeriatricMyelodysplastic syndromesOncologyPredictionPrognosis

Identifiers

PMID26073533
PMCPMC4860010
OpenAlexW2132853295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.